Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PGHL.NS
Strong BuyPremium GrowerProcter & Gamble Health Limited · Healthcare · India · $981M · Avg Vol: $921K/d
92
StockRankGet insider-trade alerts
Q
91
V
38
M
66
P/E (TTM)
25.4x
ROE
62.3%
D/E
0.0x
Dividend %
3.7%
COMPANY DESCRIPTION
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names.
FINANCIAL SUMMARY (INR)
| Year | 2022 | 2023 | 2024 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.9B | 12.1B | 11.3B | 13.9B | 6.1% | 14.3B | 15.2B | 17.2B | 11.3% |
| EPS (INR) | 116.00 | 138.00 | 121.00 | 197.00 | 14.2% | 215.16 | 211.76 | 246.21 | 11.8% |
| Shares | 16.6M | 16.6M | 16.6M | 16.6M | 0.0% | 16.6M | — | — | — |
| Debt | 28.3M | 120.0M | 95.6M | 92.9M | 34.6% | 92.9M | — | — | — |
| Equity | 6.2B | 7.5B | 5.4B | 5.2B | -4.0% | — | — | — | — |
| Op CF | 1.7B | 2.4B | 2.3B | 3.4B | 18.8% | 3.4B | — | — | — |
| Inv CF | -255.4M | -215.0M | -68.7M | 12.6M | — | — | — | — | — |
| Fin CF | -2.9B | -984.7M | -4.2B | -3.4B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-16.6%
SMA 50SMA 200
Close
$57.57
RSI (14)
34.5
52W High
$72.77
From 52W High
0.8%
SCORE BREAKDOWN
Quality
91
ROIC
83.7%99.5
ROE
62.3%98.3
GP/Assets
126.7%98.9
Op. Margin
25.7%89.0
FCF/Assets
38.3%99.0
Piotroski
783.9
Int. Cover
50.0x89.2
D/E Ratio
0.02x80.8
Current Ratio
2.18x42.2
Value
38
P/E (TTM)
25.4x48.2
EV/EBITDA
29.4x22.1
P/FCF
29.0x48.7
P/B
17.3x6.5
P/S
6.3x35.8
Div Yield
3.7%80.2
Momentum
66
52W High %
79%65.0
RS 6M
18%79.6
SMA 50/200
1.11x77.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+14%30.9
Q Growth
45%72.4
FUNDAMENTALS
Market Cap
$981M
P/E (Forward)
22.2x
Gross Margin
74.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PGHL.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PGHL.NS | Procter & Gamble Health Limited(you) | $981M | 92 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%